Dapagliflozin propanediol is a sodium-glucose co-transporter-2 (SGLT2) inhibitor used to treat type 2 diabetes, heart failure, and chronic kidney disease. By reducing glucose reabsorption in the ...
Although both sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ...
Use of SGLT2 inhibitors before emergency surgery was not associated with an increased risk for postoperative diabetic ketoacidosis. The FDA previously issued guidance on withholding SGLT2 inhibitors ...
BOSTON -- Sodium-glucose cotransporter-2 (SGLT2) inhibitors were linked to long-term reductions in mortality risk among patients with pulmonary arterial hypertension (PAH), according to an ...
SAN DIEGO -- Benefits with empagliflozin (Jardiance) for cardiovascular and renal health linger for about a year after discontinuation, as off-drug follow-up from the EMPA-KIDNEY trial showed. During ...
HOUSTON — The benefits of SGLT2 inhibitors in slowing kidney disease progression are similar regardless of patients’ type 2 diabetes (T2D) or albuminuria status, the results of a recent meta-analysis ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Starting SGLT2 inhibitors led to a lower risk of eGFR ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A smaller proportion of patients with PAH using vs. not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback